3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
19
Neoplasm Metastasis
6
Brain Neoplasms
4
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Lung Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Salivary Gland Neoplasms
1
Rare Tumour
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Meningioma
1
Malignant Female Reproductive System Neoplasm
1
Hemangiosarcoma
1
HER2-positive Breast Cancer
1
HER2 Positive Breast Carcinoma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Ependymoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Lobular
1
Carcinoma
1
Interventions
Bevacizumab
3
Everolimus
2
tozuleristide
1
neratinib
1
icotinib
1
brigatinib
1
Sirolimus
1
Mn-PyC3A
1
Losartan
1
Lapatinib
1
Fluoresceins
1
Fluorescein
1
Endostatins
1
Axitinib
1
Aspirin
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neuroma, Acoustic
×
neratinib
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled